Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PA5108 Latanoprost Ocular Implant in Primary Open Angle Glaucoma
NCT04060758Phase 1Completed
- Sponsor
- PolyActiva
- Start
- Mar 2020
- Primary completion
- May 2025
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of PA5108 Latanoprost FA SR Ocular Implant in primary open-angle glaucoma (POAG) (4 arms), sponsored by PolyActiva. Primary endpoints: Intraocular Pressure Change at 26 weeks and Adverse Events. Started Mar 2020; status: completed.
02
Drugs
PA5108 Latanoprost FA SR Ocular Implant
03
Conditions
primary open-angle glaucoma (POAG)
Beyond the preview
Go deeper on NCT04060758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04060758.